Cefozopran monohydrochloride is a third-generation cephalosporin antibiotic that is used to treat a wide range of bacterial infections. It was first introduced in Japan in 2009 and has since gained popularity due to its broad-spectrum activity against gram-positive and gram-negative bacteria.
Q1: How Can I Obtain a Quote for a Product I'm Interested In?
To receive a quotation, send us an inquiry about the desired product.
The quote will cover pack size options, pricing, and availability details.
If applicable, estimated lead times for custom synthesis or sourcing will be provided.
Quotations are valid for 30 days, unless specified otherwise.
Q2: What Are the Payment Terms for Ordering Products?
New customers generally require full prepayment.
NET 30 payment terms can be arranged for customers with established credit.
Contact our customer service to set up a credit account for NET 30 terms.
We accept purchase orders (POs) from universities, research institutions, and government agencies.
Q3: Which Payment Methods Are Accepted?
Preferred methods include bank transfers (ACH/wire) and credit cards.
Request a proforma invoice for bank transfer details.
For credit card payments, ask sales representatives for a secure payment link.
Checks aren't accepted as prepayment, but they can be used for post-payment on NET 30 orders.
Q4: How Do I Place and Confirm an Order?
Orders are confirmed upon receiving official order requests.
Provide full prepayment or submit purchase orders for credit account customers.
Send purchase orders to sales@EVITACHEM.com.
A confirmation email with estimated shipping date follows processing.
Q5: What's the Shipping and Delivery Process Like?
Our standard shipping partner is FedEx (Standard Overnight, 2Day, FedEx International Priority), unless otherwise agreed.
You can use your FedEx account; specify this on the purchase order or inform customer service.
Customers are responsible for customs duties and taxes on international shipments.
Q6: How Can I Get Assistance During the Ordering Process?
Reach out to our customer service representatives at sales@EVITACHEM.com.
For ongoing order updates or questions, continue using the same email.
Remember, we're here to help! Feel free to contact us for any queries or further assistance.
Quick Inquiry
Note: Kindly utilize formal channels such as professional, corporate, academic emails, etc., for inquiries. The use of personal email for inquiries is not advised.
ORY-1001(trans) is a small molecule drug that has gained significant attention in the field of medical research due to its potential therapeutic effects. It is a histone deacetylase (HDAC) inhibitor that has been shown to have anti-inflammatory and anti-tumor properties.
9-Dihydro-13-acetylbaccatin III is a natural product that belongs to the taxane family of compounds. It is a diterpenoid that is found in the bark of the Pacific yew tree (Taxus brevifolia). This compound has gained significant attention due to its potent anticancer activity, which has led to the development of several chemotherapeutic agents, including paclitaxel and docetaxel.
Rocuronium is a non-depolarizing neuromuscular blocking agent that is used in anesthesia to induce muscle relaxation during surgical procedures. It is a member of the aminosteroid class of neuromuscular blocking agents and is commonly used in clinical practice due to its rapid onset and short duration of action.
Pixantrone is a synthetic anthracenedione derivative that has been developed as an anticancer agent. It is a third-generation anthracycline that has been designed to overcome the limitations of the first and second-generation anthracyclines, such as doxorubicin and epirubicin. Pixantrone has been shown to have a unique mechanism of action and a favorable safety profile, making it a promising candidate for the treatment of various types of cancer.
(-)-Bicuculline methobromide is a chemical compound that belongs to the family of alkaloids. It is a potent antagonist of the neurotransmitter gamma-aminobutyric acid (GABA) and is commonly used in scientific research to study the effects of GABAergic neurotransmission. We will also discuss the future perspectives and challenges in the use and study of (-)-Bicuculline methobromide.
Enasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase 2 (IDH2) mutations, which are commonly found in acute myeloid leukemia (AML) patients. It was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of relapsed or refractory AML patients with IDH2 mutations. Enasidenib has shown promising results in clinical trials, and its potential applications in medical, environmental, and industrial research are being explored.
CO-1686 hydrobromide is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC50=21 nM).IC50 value: 21.5±1.7 nM (EGFRL858R/T790M), 303.3 ± 26.7 nM (EGFRWT)in vitro: CO-1686 is a potent inhibitor of EGFR L858R/T790M kinase (kinact/Ki = (2.41 ± 0.30) x 105 M-1s-1) and is approximately 22-fold selective over WT EGFR (kinactt/Ki = (1.12 ± 0.14) x 104 M-1s-1). CO-1686 potently inhibited proliferation in the mutant-EGFR NSCLC cellswith GI50 values ranging from 7 - 32 nM. In comparison, the GI50 value for A431 cells, an epidermoid cell line that is driven by amplified WT EGFR(19), was 547 nM. Two cell lines expressing WT EGFR in the presence of an N- or KRAS mutation (NCI-H1299 and NCI-H358,respectively) were inhibited by CO-1686 at a concentration of 4275 and 1806 nM, respectively.in vivo: CO-1686 displays high oral bioavailability (65%) and a relatively long half-life of 2.6 hours when dosed at 20 mg/kg. Tumor-bearing mice were dosed orally once daily with CO-1686 as single agent and its effect on tumor growth was determined in several EGFR dependent xenograft models. Continuous oral dosing of CO-1686 causes dose-dependent and significant tumor growth inhibition in all EGFR-mutant models examined. At 100 mg/kg/day CO-1686 causs tumor regressions in two Erlotinib-resistant models expressing the L858R/T790M EGFR mutation, the NCI-H1975 cell line xenograft and the patient-derived lung tumor xenograft (PDX) LUM1868, while Erlotinib had no inhibitory effect on tumor growth.